TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32023547

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a‐tDCS) at 1.5 mA for 15 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study: 35138376

Group type: EXPERIMENTAL
Intervention: PVI combined with PWI (PVI+PWI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 100
Study: 34397543

Group type: EXPERIMENTAL
Intervention: De-epithelialization
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study: 32644264

Group type: EXPERIMENTAL
Intervention: Advanced carbohydrate counting (ACC)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard nutrition education (Control)
Number of subjects: 87
Study: 34402352

Group type: EXPERIMENTAL
Intervention: Intracerebral stereotactic implantation of modified bone marrow-derived mesenchymal stromal (SB623) cells
Number of subjects: 61
Study: 35710481

Group type: EXPERIMENTAL
Intervention: FOLFIRI/cetuximab
Number of subjects: 236

Group type: COMPARATOR
Intervention: FOLFIRI/bevacizumab
Number of subjects: 236
Study: 34238020

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical treatment (control)
Number of subjects: 0
Study: 33049035

Group type: EXPERIMENTAL
Intervention: DTG + 3TC
Number of subjects: 0
Study: 36078842

Group type: COMPARATOR
Intervention: Traditional material
Number of subjects: 0
Study: 34074973

Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided dry-weight reduction
Number of subjects: 71
Study: 32035624

Group type: EXPERIMENTAL
Intervention: Preflushing with saline at high speed (10 ml/s) before connecting to the catheter
Number of subjects: 4900

Group type: COMPARATOR
Intervention: Conventional injection procedure (control group)
Number of subjects: 4900

Group type: EXPERIMENTAL
Intervention: Preflushing with saline
Number of subjects: 4900
Study: 35655739

Group type: EXPERIMENTAL
Intervention: Text message-based rehabilitation program (TextRehab)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 34816795

Group type: COMPARATOR
Intervention: Immediate oral amoxicillin (dose-by-age) given three times daily for 7 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Delayed oral amoxicillin (dose-by-age) given three times daily for 7 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Immediate topical ciprofloxacin (0.3%) solution, four drops given three times daily for 7 days
Number of subjects: 22
Study: 33349617

Group type: EXPERIMENTAL
Intervention: 9-item Social Media Disorder scale
Number of subjects: 1729
Study: 35436622

Group type: EXPERIMENTAL
Intervention: Teens Achieving Mastery over Stress (TEAMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Competent Adulthood Transition with Cognitive Behavioral, Humanistic and Interpersonal Training (CATCH-IT)
Number of subjects: 0
Study: 34192431

Group type: EXPERIMENTAL
Intervention: Daratumumab group (subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Control group (bortezomib, cyclophosphamide, and dexamethasone alone)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Daratumumab group
Number of subjects: 388

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 388
Study: 32970482

Group type: EXPERIMENTAL
Intervention: Wearable activity tracker (band) worn for 60 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: ECOG score assessments by physicians, coordinators, and patients
Number of subjects: 41
Study: 34491046

Group type: EXPERIMENTAL
Intervention: Air cleaner intervention
Number of subjects: 125
Study: 36143902

Group type: EXPERIMENTAL
Intervention: Endovascular treatment with nitinol stents (NS)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Vein bypass surgery
Number of subjects: 103
Study: 33225990

Group type: EXPERIMENTAL
Intervention: Prone positioning therapy throughout the day as long as possible, with breaks according to tolerance.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group allowed prone positioning as a rescue therapy.
Number of subjects: 200
Study: 35792053

Group type: EXPERIMENTAL
Intervention: Approach bias modification (ApBM)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (sham training)
Number of subjects: 300
Study: 34001215

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP), 2 units at screening/baseline visit (day 0) or day 1; additional unit on day 3 for individuals ≥150 kg
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Camostat mesylate (200 mg per capsule, one capsule taken each in the morning, afternoon, and evening on days 1-7)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo (identical in appearance to camostat mesylate capsules, one capsule taken each morning, afternoon, and evening on days 1-7)
Number of subjects: 994
Study: 32282842

Group type: EXPERIMENTAL
Intervention: Yoga program (90 min once a week for 10 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional school sports (90 min once a week for 10 weeks)
Number of subjects: 14
Study: 34740607

Group type: EXPERIMENTAL
Intervention: Baked milk oral immunotherapy (BMOIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34054034

Group type: EXPERIMENTAL
Intervention: Nutrient modifications and individual foods/drinks investigated in experimental studies (9 nutrient modifications, 34 individual foods/drinks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nutrient modifications, foods/drinks, and eating-related behaviors investigated in pre-post studies (10 nutrient modifications, 80 foods/drinks, 11 eating-related behaviors)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nutrient modifications, foods/drinks, and eating-related behaviors reported in observational studies (8 nutrient modifications, 94 foods/drinks, 5 eating-related behaviors)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Recommendations from expert opinion articles/guidelines (51 nutrient modifications, 339 foods/drinks, 23 eating-related behaviors)
Number of subjects: 31
Study: 34642494

Group type: EXPERIMENTAL
Intervention: Bepirovirsen 300 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bepirovirsen 150 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Stable NA therapy with Bepirovirsen
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Number of subjects: 31
Study: 36065065

Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1187
Study: 33426777

Group type: EXPERIMENTAL
Intervention: Standard methods group (n = 177)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Vignette group (n = 176)
Number of subjects: 353
Study: 33506632

Group type: EXPERIMENTAL
Intervention: RME (Rapid Maxillary Expansion)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alt-RAMEC (Alternate Rapid Maxillary Expansion and Constriction)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: SA (Skeletal Anchorage)
Number of subjects: 59
Study: 35182513

Group type: EXPERIMENTAL
Intervention: Once-daily risdiplam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32868247

Group type: EXPERIMENTAL
Intervention: Modified CAC scan (80 kVp, reduced z-axis length focused on proximal-to-mid coronary arteries)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard Agatston CAC scan (120 kVp)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both groups (modified and standard CAC scans)
Number of subjects: 172
Study: 33757745

Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 300

Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 300
Study: 32127848

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg intravenously
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fentanyl 1.0 µg/kg intravenously
Number of subjects: 108
Study: 35648305

Group type: EXPERIMENTAL
Intervention: Qizi Yusi Pill (QYP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 34034808

Group type: EXPERIMENTAL
Intervention: Sulforaphane (SF)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 57
Study: 32207010

Group type: EXPERIMENTAL
Intervention: Solid fuels (wood, LPG, charcoal)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Combination of cooking fuels
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Socioeconomic factors, family size, woman's education, age
Number of subjects: 1734
Study: 33001422

Group type: EXPERIMENTAL
Intervention: ACEI (Angiotensin Converting Enzyme Inhibitor)
Number of subjects: 273

Group type: COMPARATOR
Intervention: ARB (Angiotensin II Type I Receptor Blocker)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: ACEI
Number of subjects: 273

Group type: COMPARATOR
Intervention: ARB
Number of subjects: 273
Study: 32660143

Group type: EXPERIMENTAL
Intervention: Iprodione treatment on mutant M0
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Iprodione treatment on mutant M1
Number of subjects: 112

Group type: COMPARATOR
Intervention: Iprodione treatment on wild type W0
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: RNA sequencing of mutant M‐ipro
Number of subjects: 112

Group type: COMPARATOR
Intervention: RNA sequencing of wild type W‐ipro
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Quantitative real-time PCR validation of DEGs
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Gene ontology and KEGG pathway analysis
Number of subjects: 112
Study: 34305036

Group type: EXPERIMENTAL
Intervention: Acidulated phosphate fluoride gel (APF)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neutral fluoride gel (NGel)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FVa)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Without fluoride treatment (control)
Number of subjects: 44
Study: 32559392

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) sessions (four 45- to 60-minute sessions)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no MI sessions)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 140
Study: 35543130

Group type: EXPERIMENTAL
Intervention: Cardioembolism
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Embolic stroke of undetermined source (ESUS)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Dissection
Number of subjects: 264
Study: 33646044

Group type: EXPERIMENTAL
Intervention: Q203
Number of subjects: 344
Study: 32492104

Group type: EXPERIMENTAL
Intervention: Exercise ECG
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography
Number of subjects: 3283

Group type: COMPARATOR
Intervention: Exercise ECG alone
Number of subjects: 3283
Study: 36078489

Group type: EXPERIMENTAL
Intervention: Running-specific strength training group (RSSTG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endurance training group (ETG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Concurrent training group (CTG)
Number of subjects: 30
Study: 34587808

Group type: EXPERIMENTAL
Intervention: 1 g intravenous (IV) tranexamic acid (TXA) at the time of surgery and an additional 24-hour postoperative oral regime of four 1 g doses
Number of subjects: 552

Group type: COMPARATOR
Intervention: Single preoperative intravenous dose of 1 g TXA
Number of subjects: 552

Group type: COMPARATOR
Intervention: No TXA administered
Number of subjects: 552
Study: 32387140

Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW) intervention
Number of subjects: 138
Study: 36058362

Group type: EXPERIMENTAL
Intervention: Nature walk
Number of subjects: 37

Group type: COMPARATOR
Intervention: Urban walk
Number of subjects: 37
Study: 34550055

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis, BB-12® (1×10^9 cfu/day)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis, BB-12®
Number of subjects: 192
Study: 34800364

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 plus the influenza vaccine
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo plus the influenza vaccine
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 33514449

Group type: EXPERIMENTAL
Intervention: Triple therapy (bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 32335844

Group type: EXPERIMENTAL
Intervention: BIIB059 (anti-BDCA2 monoclonal antibody) administered intravenously and subcutaneously, dosage not specified.
Number of subjects: 109
Study: 35271465

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Endovascular surgery
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study: 34406350

Group type: EXPERIMENTAL
Intervention: Contact force‐guided radiofrequency ablation
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: 4‐minute cryoballoon ablation
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: 2‐minute cryoballoon ablation
Number of subjects: 346
Study: 35122877

Group type: EXPERIMENTAL
Intervention: 45-min moderate-intensity exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: 60-min moderate-intensity exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control session (55-min rest)
Number of subjects: 24
Study: 34251873

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin (100 mg/m2) and docetaxel (85 mg/m2) followed by durvalumab (750 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy with cisplatin and docetaxel
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by durvalumab
Number of subjects: 68
Study: 34143054

Group type: EXPERIMENTAL
Intervention: Proposed infrared image impulse-noise-suppression method using tensor robust principal component analysis and truncated total variation
Number of subjects: 0

Group type: COMPARATOR
Intervention: State-of-the-art methods
Number of subjects: 0
Study: 32436809

Group type: EXPERIMENTAL
Intervention: N-Butyl Cyanoacrylate (NBCA) sac embolization
Number of subjects: 44

Group type: COMPARATOR
Intervention: EVAR without sac embolization (Control)
Number of subjects: 44
Study: 34420205

Group type: EXPERIMENTAL
Intervention: Task-specific physiotherapist-led training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Parent-led home programme
Number of subjects: 62
Study: 33129910

Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy (2 concurrent cycles of cisplatin followed by 4 cycles of carboplatin/paclitaxel)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 660
Study: 33793460

Group type: EXPERIMENTAL
Intervention: mRNA BNT162b2 and mRNA-1273 COVID-19 vaccines (full immunization, ≥14 days after second dose)
Number of subjects: 3950

Group type: EXPERIMENTAL
Intervention: mRNA BNT162b2 and mRNA-1273 COVID-19 vaccines (partial immunization, ≥14 days after first dose and before second dose)
Number of subjects: 3950

Group type: COMPARATOR
Intervention: Unvaccinated participants
Number of subjects: 3950
Study: 32876987

Group type: EXPERIMENTAL
Intervention: Whey protein (30 g in 200 mL warm water at fasting time for 4 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (30 g in 200 mL warm water at fasting time for 4 weeks)
Number of subjects: 50
Study: 36079822

Group type: EXPERIMENTAL
Intervention: Nutritional supplements, diet education, and standard care
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 29
Study: 33354755

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention involving medication therapy problem identification and recommendations
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Medication therapy problems related to indication, effectiveness, and safety
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Recommendations from pharmacists
Number of subjects: 105
Study: 32383544

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (specifically gradient boosting algorithm)
Number of subjects: 16440
Study: 32573121

Group type: EXPERIMENTAL
Intervention: Scleral buckling (SB)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Drainage–injection–pneumoretinopexy (DIP)
Number of subjects: 58
Study: 32925516

Group type: EXPERIMENTAL
Intervention: Educational video (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no video, n=11)
Number of subjects: 22
Study: 35344567

Group type: EXPERIMENTAL
Intervention: Cognitive paradigms of different complexities and durations (naming words beginning with P-, R-, V- and serial subtractions of 100–2, 100–7, 1000–17)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cognitive paradigms of different complexities and durations
Number of subjects: 16
Study: 34050594

Group type: EXPERIMENTAL
Intervention: High-dose losartan
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-dose losartan
Number of subjects: 100
Study: 35636444

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus FOLFOXIRI plus bevacizumab
Number of subjects: 218

Group type: COMPARATOR
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 218
Study: 33797023

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 95
Study: 32026625

Group type: EXPERIMENTAL
Intervention: Test Adhesive 1
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Test Adhesive 2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Reference adhesive (PMV/MA-based)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No adhesive
Number of subjects: 23
Study: 36222002

Group type: EXPERIMENTAL
Intervention: Perichondrium–cartilage island repair
Number of subjects: 84

Group type: COMPARATOR
Intervention: TMF repair (Control)
Number of subjects: 84
Study: 33966293

Group type: EXPERIMENTAL
Intervention: Cumulative melphalan exposure among cases (median 988 mg; IQR 644-1640)
Number of subjects: 26627

Group type: COMPARATOR
Intervention: Cumulative melphalan exposure among controls (median 578 mg; IQR 360-967)
Number of subjects: 26627

Group type: EXPERIMENTAL
Intervention: Median time to AML/MDS development
Number of subjects: 26627
Study: 32248243

Group type: EXPERIMENTAL
Intervention: GAD-alum (20 μg, administered twice or three times)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alum alone (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GAD-alum
Number of subjects: 0
Study: 36737698

Group type: EXPERIMENTAL
Intervention: 10 mg triamcinolone acetonide
Number of subjects: 84

Group type: COMPARATOR
Intervention: 40 mg triamcinolone acetonide
Number of subjects: 84
Study: 33735594

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (Ferinject) 1,000 mg or 15 mg/kg if weight <66.7 kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Iron dextran (Cosmofer) 20 mg iron/kg body weight
Number of subjects: 56

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 56
Study: 34305108

Group type: EXPERIMENTAL
Intervention: Independent physical activity programme for 2 months
Number of subjects: 106

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 106
Study: 32059954

Group type: EXPERIMENTAL
Intervention: All-inside quadrupled semitendinosus autograft (AIST)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB)
Number of subjects: 64
Study: 35873404

Group type: EXPERIMENTAL
Intervention: 300 mg of ashwagandha root extract twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 50
Study: 32068472

Group type: EXPERIMENTAL
Intervention: Microneedling combined with PRP (4 sessions)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Microneedling combined with PRP (6 sessions)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fractional Er: YAG laser (4 sessions)
Number of subjects: 45
Study: 32583313

Group type: EXPERIMENTAL
Intervention: Allisartan 240 mg/day and lifestyle modification
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lifestyle modification
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Allisartan
Number of subjects: 72
Study: 36344008

Group type: EXPERIMENTAL
Intervention: eMOM GDM app with standard antenatal care
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 200
Study: 34602054

Group type: EXPERIMENTAL
Intervention: Mentoring support provided to OTs via phone or Microsoft Teams (88.6-100%), email, and SMS text messages.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mentoring support for OTs
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mentoring as an implementation strategy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mentoring
Number of subjects: 41
Study: 33589590

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release for 12 weeks
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores for cardioembolic stroke
Number of subjects: 307
Study: 33646327

Group type: EXPERIMENTAL
Intervention: Response inhibition training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 33000160

Group type: EXPERIMENTAL
Intervention: 4 g oral l-histidine daily for 8 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.8 g l-histidine daily for 12 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 4 g l-histidine daily
Number of subjects: 73
Study: 35511938

Group type: EXPERIMENTAL
Intervention: Vopratelimab alone
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Vopratelimab with nivolumab
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Vopratelimab with ICOS-hi CD4 T-cells
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Potential genomic predictive biomarker
Number of subjects: 201